Literature DB >> 28520998

Medications for the prevention and treatment of travellers' diarrhea.

David N Taylor1, Davidson H Hamer2,3, David R Shlim4.   

Abstract

BACKGROUND: . Travellers' diarrhea (TD) remains one of the most common illnesses encountered by travellers to less developed areas of the world. Because bacterial pathogens such as enterotoxigenic Escherichia coli (ETEC), enteroaggregative E. coli , Campylobacter spp. and Shigella spp. are the most frequent causes, antibiotics have been useful in both prevention and treatment of TD. METHODS.: Results of trials that assessed the use of medications for the prevention and treatment of TD were identified through PubMed and MEDLINE searches using search terms 'travellers' diarrhea', 'prevention' and 'treatment'. References of articles were also screened for additional relevant studies. RESULTS.: Prevention of TD with antibiotics has been recommended only under special circumstances. Doxycycline, trimethoprim-sulfamethoxazole, fluoroquinolones and rifaximin have been used for prevention, but at present the first three antibiotics may have limited use secondary to increasing resistance, leaving rifaximin as the only current option. Bismuth subsalicylate (BSS) (Pepto-Bismol tablets) is also an option for prophylaxis. Treatment with antibiotics has been recommended for moderate to severe TD. Azithromycin is the drug of choice, especially in Asia where Campylobacter is common. Fluoroquinolone antibiotics continue to be effectively used in Latin America and Africa where ETEC is predominant. BSS and loperamide (LOP) also are effective as standalone treatments. LOP may be used alone for treatment of mild TD or in conjunction with antibiotics for treatment of TD.
CONCLUSIONS: . Historically, antibiotic prophylaxis has not been routinely recommended and has been reserved for special circumstances such as when a traveller with an underlying illness cannot tolerate TD. Antibiotics with or without LOP have been useful in shortening the duration and severity of TD. Emerging antibiotic resistance, limited new antibiotic alternatives and faecal carriage of antibiotic-resistant bacteria by travellers may prompt a re-evaluation of classic recommendations for treatment and prevention of TD with antibiotics. © International Society of Travel Medicine, 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  Traveller’s diarrhea; azithromycin; bismuth subsalicylate; fluoroquinolone; loperamide; prevention; treatment

Mesh:

Substances:

Year:  2017        PMID: 28520998     DOI: 10.1093/jtm/taw097

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  8 in total

1.  Lentils and Yeast Fibers: A New Strategy to Mitigate Enterotoxigenic Escherichia coli (ETEC) Strain H10407 Virulence?

Authors:  Thomas Sauvaitre; Florence Van Herreweghen; Karen Delbaere; Claude Durif; Josefien Van Landuyt; Khaled Fadhlaoui; Ségolène Huille; Frédérique Chaucheyras-Durand; Lucie Etienne-Mesmin; Stéphanie Blanquet-Diot; Tom Van de Wiele
Journal:  Nutrients       Date:  2022-05-21       Impact factor: 6.706

Review 2.  Acute Bacterial Gastroenteritis.

Authors:  James M Fleckenstein; F Matthew Kuhlmann; Alaullah Sheikh
Journal:  Gastroenterol Clin North Am       Date:  2021-04-23       Impact factor: 3.806

3.  In vitro evaluation of the antitumor effect of bismuth lipophilic nanoparticles (BisBAL NPs) on breast cancer cells.

Authors:  Rene Hernandez-Delgadillo; Claudia María García-Cuéllar; Yesennia Sánchez-Pérez; Nayely Pineda-Aguilar; Marco Antonio Martínez-Martínez; Eyra Elvyra Rangel-Padilla; Sergio Eduardo Nakagoshi-Cepeda; Juan Manuel Solís-Soto; Rosa Isela Sánchez-Nájera; María Argelia Akemi Nakagoshi-Cepeda; Shankararaman Chellam; Claudio Cabral-Romero
Journal:  Int J Nanomedicine       Date:  2018-10-05

4.  Antibiotic Resistance of Campylobacter Species in a Pediatric Cohort Study.

Authors:  Francesca Schiaffino; Josh M Colston; Maribel Paredes-Olortegui; Ruthly François; Nora Pisanic; Rosa Burga; Pablo Peñataro-Yori; Margaret N Kosek
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 5.  Travelers' Diarrhea: A Clinical Review.

Authors:  Alexander K C Leung; Amy A M Leung; Alex H C Wong; Kam L Hon
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2019

6.  Multi-targeted properties of the probiotic saccharomyces cerevisiae CNCM I-3856 against enterotoxigenic escherichia coli (ETEC) H10407 pathogenesis across human gut models.

Authors:  Charlène Roussel; Kim De Paepe; Wessam Galia; Jana de Bodt; Sandrine Chalancon; Sylvain Denis; Françoise Leriche; Pascal Vandekerkove; Nathalie Ballet; Stéphanie Blanquet-Diot; Tom Van de Wiele
Journal:  Gut Microbes       Date:  2021 Jan-Dec

7.  Genome-wide screens reveal Escherichia coli genes required for growth of T1-like phage LL5 and V5-like phage LL12.

Authors:  Denish Piya; Lauren Lessor; Brian Koehler; Ashley Stonecipher; Jesse Cahill; Jason J Gill
Journal:  Sci Rep       Date:  2020-05-15       Impact factor: 4.379

Review 8.  A review of antibiotic prophylaxis for traveler's diarrhea: past to present.

Authors:  Ajib Diptyanusa; Thundon Ngamprasertchai; Watcharapong Piyaphanee
Journal:  Trop Dis Travel Med Vaccines       Date:  2018-11-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.